The Journal of Experimental Medicine
Torrey Pines Biolabs
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article
Right arrow Full Text
Right arrow Full Text (PDF, 196K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grumont, R. J.
Right arrow Articles by Gerondakis, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grumont, R. J.
Right arrow Articles by Gerondakis, S.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Substance via MeSH
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
© The Rockefeller University Press, 0022-1007/1998/3/663/ $5.00
The Journal of Experimental Medicine, Volume 187, Number 5, March 2, 1998 663-674


Articles

B Lymphocytes Differentially Use the Rel and Nuclear Factor {kappa}B1 (NF-{kappa}B1) Transcription Factors to Regulate Cell Cycle Progression and Apoptosis in Quiescent and Mitogen-activated Cells

Raelene J. Grumont*, Ian J. Rourke*, Lorraine A. O'Reilly*, Andreas Strasser*, Kensuke Miyake{ddagger}, William Sha§, and Steve Gerondakis*

From * The Walter and Eliza Hall Institute of Medical Research, Post Office The Royal Melbourne Hospital, Victoria 3050, Australia; the {ddagger} Department of Immunology, Saga Medical School, Nabeshima, Saga 849, Japan; and the § University of California, Berkeley, California 94720

Rel and nuclear factor (NF)-{kappa}B1, two members of the Rel/NF-{kappa}B transcription factor family, are essential for mitogen-induced B cell proliferation. Using mice with inactivated Rel or NF-{kappa}B1 genes, we show that these transcription factors differentially regulate cell cycle progression and apoptosis in B lymphocytes. Consistent with an increased rate of mature B cell turnover in naive nfkb1–/– mice, the level of apoptosis in cultures of quiescent nfkb1–/–, but not c-rel–/–, B cells is higher. The failure of c-rel–/– or nfkb1–/– B cells to proliferate in response to particular mitogens coincides with a cell cycle block early in G1 and elevated cell death. Expression of a bcl-2 transgene prevents apoptosis in resting and activated c-rel–/– and nfkb1–/– B cells, but does not overcome the block in cell cycle progression, suggesting that the impaired proliferation is not simply a consequence of apoptosis and that Rel/NF-{kappa}B proteins regulate cell survival and cell cycle control through independent mechanisms. In contrast to certain B lymphoma cell lines in which mitogen-induced cell death can result from Rel/NF-{kappa}B–dependent downregulation of c-myc, expression of c-myc is normal in resting and stimulated c-rel–/– B cells, indicating that target gene(s) regulated by Rel that are important for preventing apoptosis may differ in normal and immortalized B cells. Collectively, these results are the first to demonstrate that in normal B cells, NF-{kappa}B1 regulates survival of cells in G0, whereas mitogenic activation induced by distinct stimuli requires different Rel/NF-{kappa}B factors to control cell cycle progression and prevent apoptosis.


The authors thank Dr. David Huang for technical advice, Dr. Frank Battye and colleagues for assistance with cell sorting, and Ms. Julie Merryfull for animal husbandry.

This work is supported by the National Health and Medical Research Council (Australia), the Anti-Cancer Council of Victoria, the Australian Cooperative Research Centre grant (No. 91007), and Commonwealth AIDS Research Grant (No. 971274).

Address correspondence to Steve Gerondakis, The Walter and Eliza Hall Institute of Medical Research, P.O. The Royal Melbourne Hospital, Victoria 3050, Australia. Phone: 61-3-93452542; Fax: 61-3-93470852; E-mail: gerondakis{at}wehi.edu.au

1 Abbreviations used in this paper: BrdU, 5-bromo-2-deoxyuridine; mRNA, messenger RNA; PI, propidium iodide.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS